92 related articles for article (PubMed ID: 25424883)
1. Continued value in understanding viral kinetic decline during interferon-free therapy for HCV.
Meissner EG
Liver Int; 2015 Feb; 35(2):295-6. PubMed ID: 25424883
[No Abstract] [Full Text] [Related]
2. Understanding hepatitis C viral dynamics with direct-acting antiviral agents due to the interplay between intracellular replication and cellular infection dynamics.
Guedj J; Neumann AU
J Theor Biol; 2010 Dec; 267(3):330-40. PubMed ID: 20831874
[TBL] [Abstract][Full Text] [Related]
3. Synthetic lipophilic antioxidant BO-653 suppresses HCV replication.
Yasui F; Sudoh M; Arai M; Kohara M
J Med Virol; 2013 Feb; 85(2):241-9. PubMed ID: 23192857
[TBL] [Abstract][Full Text] [Related]
4. Inhibitory effects of Pycnogenol® on hepatitis C virus replication.
Ezzikouri S; Nishimura T; Kohara M; Benjelloun S; Kino Y; Inoue K; Matsumori A; Tsukiyama-Kohara K
Antiviral Res; 2015 Jan; 113():93-102. PubMed ID: 25446333
[TBL] [Abstract][Full Text] [Related]
5. Hydroxyurea as an inhibitor of hepatitis C virus RNA replication.
Nozaki A; Morimoto M; Kondo M; Oshima T; Numata K; Fujisawa S; Kaneko T; Miyajima E; Morita S; Mori K; Ikeda M; Kato N; Tanaka K
Arch Virol; 2010 Apr; 155(4):601-5. PubMed ID: 20204428
[TBL] [Abstract][Full Text] [Related]
6. A serine palmitoyltransferase inhibitor blocks hepatitis C virus replication in human hepatocytes.
Katsume A; Tokunaga Y; Hirata Y; Munakata T; Saito M; Hayashi H; Okamoto K; Ohmori Y; Kusanagi I; Fujiwara S; Tsukuda T; Aoki Y; Klumpp K; Tsukiyama-Kohara K; El-Gohary A; Sudoh M; Kohara M
Gastroenterology; 2013 Oct; 145(4):865-73. PubMed ID: 23791700
[TBL] [Abstract][Full Text] [Related]
7. A Hepatitis C virus-host interaction involved in viral replication: toward the identification of antiviral targets.
Suzuki T
Jpn J Infect Dis; 2010 Sep; 63(5):307-11. PubMed ID: 20858994
[TBL] [Abstract][Full Text] [Related]
8. The hepatitis C virus life cycle as a target for new antiviral therapies.
Pawlotsky JM; Chevaliez S; McHutchison JG
Gastroenterology; 2007 May; 132(5):1979-98. PubMed ID: 17484890
[TBL] [Abstract][Full Text] [Related]
9. Hepatitis C viral kinetic models.
Herrmann E; Zeuzem S
Cell Death Differ; 2003 Jan; 10 Suppl 1():S7-8. PubMed ID: 12655337
[No Abstract] [Full Text] [Related]
10. Hepatitis C virus replication in mouse cells is restricted by IFN-dependent and -independent mechanisms.
Nandakumar R; Finsterbusch K; Lipps C; Neumann B; Grashoff M; Nair S; Hochnadel I; Lienenklaus S; Wappler I; Steinmann E; Hauser H; Pietschmann T; Kröger A
Gastroenterology; 2013 Dec; 145(6):1414-23.e1. PubMed ID: 23973921
[TBL] [Abstract][Full Text] [Related]
11. Assessment of the activity of directly acting antivirals and other products against different genotypes of hepatitis C virus prevalent in resource-poor countries.
Khan H; Paeshuyse J; Murad S; Neyts J
Antiviral Res; 2016 Jan; 125():43-5. PubMed ID: 26593977
[TBL] [Abstract][Full Text] [Related]
12. Does fluvastatin favour HCV replication in vivo? A pilot study on HIV-HCV co-infected patients.
Bader T
J Viral Hepat; 2010 Mar; 17(3):227. PubMed ID: 19758277
[No Abstract] [Full Text] [Related]
13. Caffeine inhibits hepatitis C virus replication in vitro.
Batista MN; Carneiro BM; Braga AC; Rahal P
Arch Virol; 2015 Feb; 160(2):399-407. PubMed ID: 25491197
[TBL] [Abstract][Full Text] [Related]
14. Twenty-four hour kinetics of hepatitis C virus and antiviral effect of alpha-interferon.
Boulestin A; Kamar N; Sandres-Sauné K; Legrand-Abravanel F; Alric L; Vinel JP; Rostaing L; Izopet J
J Med Virol; 2006 Mar; 78(3):365-71. PubMed ID: 16419107
[TBL] [Abstract][Full Text] [Related]
15. 3-Amino-2(5H)furanones as inhibitors of subgenomic hepatitis C virus RNA replication.
Iannazzo D; Piperno A; Romeo G; Romeo R; Chiacchio U; Rescifina A; Balestrieri E; Macchi B; Mastino A; Cortese R
Bioorg Med Chem; 2008 Nov; 16(21):9610-5. PubMed ID: 18835180
[TBL] [Abstract][Full Text] [Related]
16. Clinical trial investigates two experimental HCV drugs.
AIDS Patient Care STDS; 2010 Apr; 24(4):270. PubMed ID: 20402017
[No Abstract] [Full Text] [Related]
17. Early prediction of hepatitis C virus (HCV) infection relapse in nonresponders to primary interferon therapy by means of HCV RNA whole-blood analysis.
Watkins-Riedel T; Ferenci P; Steindl-Munda P; Gschwantler M; Mueller C; Woegerbauer M
Clin Infect Dis; 2004 Dec; 39(12):1754-60. PubMed ID: 15578395
[TBL] [Abstract][Full Text] [Related]
18. Hepatitis C virus genetic variability in patients undergoing antiviral therapy.
Cristina J; del Pilar Moreno M; Moratorio G
Virus Res; 2007 Aug; 127(2):185-94. PubMed ID: 17449128
[TBL] [Abstract][Full Text] [Related]
19. Hepatitis C virus dynamics and cellular gene expression in uPA-SCID chimeric mice with humanized livers during intravenous silibinin monotherapy.
DebRoy S; Hiraga N; Imamura M; Hayes CN; Akamatsu S; Canini L; Perelson AS; Pohl RT; Persiani S; Uprichard SL; Tateno C; Dahari H; Chayama K
J Viral Hepat; 2016 Sep; 23(9):708-17. PubMed ID: 27272497
[TBL] [Abstract][Full Text] [Related]
20. Macromolecular (pro)drugs with concurrent direct activity against the hepatitis C virus and inflammation.
Wohl BM; Smith AA; Jensen BE; Zelikin AN
J Control Release; 2014 Dec; 196():197-207. PubMed ID: 25451544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
